Evidence map›Paper›PMID 37915847›Full record

ArticleFrontiers in cellular and infection microbiology2023

Gut microbiota in adults with moyamoya disease: characteristics and biomarker identification.

Xiaofan Yu, Peicong Ge, Yuanren Zhai, Wei Liu, Qian Zhang, Xun Ye, Xingju Liu, Rong Wang, Yan Zhang, Jizong Zhao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Peripheral bloodStroke and vascular neurology · 2025
    Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Xiaofan YuDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Peicong GeDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuanren ZhaiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wei LiuDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Qian ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xun YeDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xingju LiuDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Rong WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yan ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jizong ZhaoDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Dong ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Chinese Institute for Brain Research · CNNational Clinical Research Center for Digestive Diseases · CNBeijing Tian Tan Hospital · CNCapital Medical University · CNBeijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: When it comes to the onset of moyamoya disease (MMD), environmental variables are crucial. Furthermore, there is confusion about the relationship between the gut microbiome, an environmental variable, and MMD. Consequently, to identify the particular bacteria that cause MMD, we examined the gut microbiome of MMD individuals and healthy controls (HC). Methods: A prospective case-control investigation was performed from June 2021 to May 2022. The fecal samples of patients with MMD and HC were obtained. Typically, 16S rRNA sequencing was employed to examine their gut microbiota. The QIIME and R softwares were used to examine the data. The linear discriminant analysis effect size analysis was used to determine biomarkers. Multivariate analysis by linear models (MaAsLin)2 were used to find associations between microbiome data and clinical variables. Model performance was assessed using the receiver operating characteristic curve and the decision curve analysis. Results: This investigation involved a total of 60 MMD patients and 60 HC. The MMD group's Shannon and Chao 1 indices were substantially lower than those of the HC cohort. β-diversity was significantly different in the weighted UniFrac distances. At the phylum level, the relative abundance of Conclusions: The gut microbiota was altered in individuals with MMD, and was characterized by increased abundance of

Indexed as

Gastrointestinal MicrobiomeMoyamoya DiseaseAdultBacteriaBifidobacteriumBiomarkersFecesFusobacteriumHumansRNA, Ribosomal, 16SBiomarkersRNA, Ribosomal, 16Sadultsbiomarkercharacteristicsgut microbiotamoyamoya disease

Identifiers

PMID37915847
PMCPMC10616959
OpenAlexW4387703411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.